Table 2:
Clinicodemographic characteristics by diabetes status among patients with cancer (n=3,512)
| Totala | Prediabetes | Diabetes | Neither | p-value | |
|---|---|---|---|---|---|
| Study Population n (%) | 3,512 (100) | 745 (21.2) | 1,145 (32.6) | 1,622 (46.2) | |
| Age (years) mean (SD)b | 57.8 (14.0) | 57.4 (14.1) | 60.4 (13.1) | 56.2 (14.2) | <0.001 |
| Age categorized n (%)b | <0.001 | ||||
| <50 years | 854 (24.3) | 194 (26.0) | 206 (18.0) | 454 (28.0) | |
| 50 to 64 years | 1,440 (41.0) | 293 (39.3) | 463 (40.4) | 684 (42.2) | |
| 65 to 79 years | 1,091 (31.1) | 238 (31.9) | 423 (36.9) | 430 (26.5) | |
| 80+ years | 127 (3.6) | 20 ( 2.7) | 53 ( 4.6) | 54 ( 3.3) | |
| Sex n (%) | 0.02 | ||||
| Female | 1,724 (49.1) | 360 (48.3) | 529 (46.2) | 835 (51.5) | |
| Male | 1,788 (50.9) | 385 (51.7) | 616 (53.8) | 787 (48.5) | |
| Race and Ethnicity n (%) | <0.001 | ||||
| Non-Hispanic White | 3,177 (90.5) | 678 (91.0) | 1,006 (87.9) | 1,493 (92.0) | |
| Non-Hispanic Black | 18 (0.5) | 10 (1.3) | 2 ( 0.2) | 6 ( 0.4) | |
| Non-Hispanic Asian | 38 (1.1) | 7 ( 0.9) | 15 (1.3) | 16 (1.0) | |
| Non-Hispanic Otherc | 142 (4.0) | 26 (3.5) | 54 (4.7) | 62 (3.8) | |
| Hispanic | 137 (3.9) | 24 (3.2) | 68 (5.9) | 45 (2.8) | |
| BMI kg/m2 mean (SD)d | 29.1 (6.6) | 28.1 (5.8) | 31.3 (7.7) | 28.0 (5.8) | <0.001 |
| BMI kg/m2 category n (%)d | <0.001 | ||||
| Underweight (<18.5) | 33 (0.9) | 7 (0.9) | 9 (0.8) | 17 (1.0) | |
| Normal (18.5 – 24.99) | 814 (23.2) | 198 (26.6) | 185 (16.2) | 431 (26.6) | |
| Overweight (25.0 – 29.99) | 1,004 (28.6) | 222 (29.8) | 281 (24.5) | 501 (30.9) | |
| Obese (>=30) | 1,118 (31.8) | 210 (28.2) | 482 (42.1) | 426 (26.3) | |
| Unknown | 543 (15.5) | 108 (14.5) | 188 (16.4) | 247 (15.2) | |
| Population n (%)e | 0.31 | ||||
| Rural | 1,125 (32) | 223 (29.9) | 362 (31.6) | 540 (33.3) | |
| Non-Rural | 2,357 (67.1) | 515 (69.1) | 770 (67.2) | 1,072 (66.1) | |
| Unknown | 30 (0.9) | 7 (0.9) | 13 (1.1) | 10 (0.6) | |
| State of Residence n (%)f | <0.001 | ||||
| Utah | 2,464 (70.2) | 557 (74.8) | 818 (71.4) | 1,089 (67.1) | |
| Idaho | 425 (12.1) | 65 (8.7) | 146 (12.8) | 214 (13.2) | |
| Wyoming | 274 (7.8) | 45 (6.0) | 86 (7.5) | 143 (8.8) | |
| Nevada | 168 (4.8) | 39 (5.2) | 54 (4.7) | 75 (4.6) | |
| Other | 181 (5.2) | 39 (5.2) | 41 (3.6) | 101 (6.2) | |
| Cancer Stage n (%) | <0.001 | ||||
| Stage 0-I | 872 (24.8) | 137 (18.4) | 226 (19.7) | 509 (31.4) | |
| Stage II | 638 (18.2) | 107 (14.4) | 208 (18.2) | 323 (19.9) | |
| Stage III | 553 (15.7) | 94 (12.6) | 167 (14.6) | 292 (18.0) | |
| Stage IV | 543 (15.5) | 153 (20.5) | 199 (17.4) | 191 (11.8) | |
| Unknown/ Not Applicableg | 906 (25.8) | 254 (34.1) | 345 (30.1) | 307 (18.9) | |
| Cancer treatment n (%) | |||||
| Surgery | 2,957 (84.2) | 594 (79.7) | 945 (82.5) | 1,418 (87.4) | <0.001 |
| Chemotherapy | 1,458 (41.5) | 425 (57.0) | 548 (48.0) | 485 (29.9) | <0.001 |
| Radiation | 1,035 (29.5) | 251 (33.7) | 349 (30.5) | 435 (26.8) | 0.002 |
| Hormone therapy | 731 (20.8) | 169 (22.7) | 204 (17.8) | 358 (22.1) | 0.01 |
| Immunotherapy | 339 (9.7) | 99 (13.3) | 122 (10.7) | 118 (7.3) | <0.001 |
| Glucocorticoids | 2,938 (83.7) | 656 (88.1) | 972 (84.9) | 1,310 (80.8) 1.5) | <0.001 |
| Cancer Sequence Number n (%) | <0.001 | ||||
| 00 – only one primary cancer | 3,084 (87.8) | 632 (84.8) | 977 (85.3) | 1,475 (90.9) | |
| 01 – multiple primary cancer | 428 (12.2) | 113 (15.2) | 168 (14.7) | 147 (9.1) |
a
Not all %s add up to 100 because of rounding decimal places;
b
At cancer diagnosis;
c
American Indian/Alaska Native, Hawaiian/Other Pacific Islander, Other, or Unknown;
d
Body Mass Index, at cancer diagnosis (90 days window before and after cancer diagnosis);
e
Determined from RUCA score on zip code;
f
Determined from last known residence;
g
Brain and nervous system cancers are not routinely staged; n=number; SD=standard deviation; BMI=body mass index